1. Home
  2. Clinical Topics
  3. Cardio-Pulmonary
  4. FDA recommends more conservative dosing guidelines for erythropoiesis-stimulating agents
Cardio-PulmonaryClinical TopicsDrugs and DevicesNewsWeb Exclusives

FDA recommends more conservative dosing guidelines for erythropoiesis-stimulating agents

Share

The U.S. Food and Drug Administration (FDA) is recommending more conservative dosing guidelines for erythropoiesis-stimulating agents (ESAs) when they are used to treat anemia in patients with chronic kidney disease. FDA cites increased risks of stroke and other cardiovascular events as the reason behind the change. Read more.

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts